

## Special Issue

# Monoclonal Antibody Research in the Era of COVID-19

### Message from the Guest Editor

A monoclonal antibody is an antibody originating from a unique B cell lineage, binding only to the same epitope with high affinity for its target. Over the years, monoclonal antibodies have been used or heavily investigated for their potential role against many diseases, including bacterial and viral infection and cancer. Likewise, antibody-based therapy alone or in combination with other treatments has been demonstrated to be effective for both the early and late stages of SARS-COV-2 infection in the past three years. In this Special Issue, we invite reviews, research papers, and clinical trial applications elaborating on mechanisms whereby monoclonal antibodies act directly and indirectly against various SARS-COV-2 variants and developing strategies and technologies for antibody engineering related to COVID-19 to enhance immune protection. Additionally, new combinations of multiple monoclonal antibodies targeting different antigens or bispecific antibodies to overcome the viral escape phenomenon are of interest.

---

### Guest Editor

Dr. Miaomiao Shi

Missiakas-Schneewind Lab, University of Chicago, Building 204 9700  
S. Cass Avenue, Lemont, IL 60439, USA

---

### Deadline for manuscript submissions

closed (1 December 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/154019](https://mdpi.com/si/154019)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[vaccines](https://vaccines.mdpi.com)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).